HPV clearance in postpartum period of HIV-positive and negative women: a prospective follow-up study

BMC Infectious Diseases

Silvana Maria Quintana¹  Rodrigo Augustus Amaral de Morais³  Aparecida Yulie Yamamoto¹  Renata Toscano Simoes³  Geraldo Duarte¹  Patricia Pereira dos Santos Melli¹  Francisco Inacio Bastos⁴  Emilia Moreira Jalil² 

[1] Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Sao Paulo, Brazil;ICICT/ENSP - Fundação Oswaldo Cruz - FIOCRUZ, Biblioteca de Manguinhos suite 229, Av. Brasil 4365, Rio de Janeiro RJ 21045-900, Brazil;Instituto de Ensino e Pesquisa da Santa Casa de, Belo Horizonte, Brazil;CAPES Visiting scholar, Imperial College London, London, UK

关键词: Polymerase Chain Reaction (PCR);    Postpartum Period;    Pregnancy;    HIV;    Human Papillomavirus;   

Others  :  1138272
DOI  :  10.1186/1471-2334-13-564

 received in 2013-05-03, accepted in 2013-11-26,  发布年份 2013

【 摘 要 】

Background

HPV persistence is a key determinant of cervical carcinogenesis. The influence of postpartum on HPV clearance has been debated. This study aimed to assess HPV clearance in later pregnancy and postpartum among HIV-positive and negative women.

Methods

We conducted a follow-up study with 151 HPV-positive women coinfected with HIV, in 2007–2010. After baseline assessment, all women were retested for HPV infection using PCR in later pregnancy and after delivery. Multivariable logistic regressions assessed the putative association of covariates with HPV status in between each one of the successive visits.

Results

Seventy-one women (47%) have eliminated HPV between the baseline visit and their second or third visits. HIV-positive women took a significantly longer time (7.0 ± 3.8 months) to clear HPV, compared to those not infected by HIV (5.9 ± 3.0 months). HPV clearance was significantly more likely to take place after delivery than during pregnancy (84.5% x 15.5%).

Conclusions

Both HIV-positive and negative women presented a significant reduction in HPV infection during the postpartum period. HIV-positive status was found to be associated with a longer period of time to clear HPV infection in pregnant women.

【 授权许可】

   
2013 Jalil et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Bruni L, Diaz M, Castellsagué M, Ferrer E, Bosch FX, de Sanjosé S: Cervical Human Papillomavirus Prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis 2010, 202:1789-1799.
• [2]Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD: Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998, 338:423-428.
• [3]Plummer M, Schiffman M, Castle PE, Maucort-Boulch D, Wheeler CM: A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion. J Infect Dis 2007, 195:1582-1589.
• [4]Rodriguez AC, Schiffman M, Herrero R, Wacholder S, Hildesheim A, Castle PE, Solomon D, Burk R: Proyecto epidemiológico Guanacaste group: rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. J Natl Cancer Inst 2008, 100:513-517.
• [5]Winer RL, Hughes JP, Feng Q, Xi LF, Cherne S, O’Reilly S, Kiviat NB, Koutsky LA: Early natural history of incident type-specific human papillomavirus in newly sexually active young women. Cancer Epidemiol Biomarkers Prev 2011, 20:699-707.
• [6]Kjaer SK, van den Brule AJC, Paull G, Svare EI, Sherman ME, Thomsen BL, Suntum M, Bock JE, Poll PA, Meijer CJ: Type specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: population based prospective follow up study. BMJ 2002, 325:572-578.
• [7]Koshiol J, Lindsay L, Pimenta JM, Poole C, Jenkins D, Smith JS: Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis. Am J Epidemiol 2008, 168:123-137.
• [8]Stanley M: Pathology and epidemiology of HPV infection in females. Gynecol Oncol 2010, 117:S5-S10.
• [9]Louvanto K, Syrjanen KJ, Rintala MA, Grénman SE, Syrjanen SM: Human papillomavirus and predictors of cervical intraepithelial neoplasia among young mothers in a prospective follow-up study. Acta Obstet Gynecol Scand 2011, 90:167-173.
• [10]Naucler P, Ryd W, Tomberg S, Strand A, Wadell G, Elfgren K, Rådberg T, Strander B, Johansson B, Forslund O, Hansson BG, Rylander E, Dillner J: Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med 2007, 357:1589-1597.
• [11]Castle PE, Rodriguez AC, Burk RD, Herrero R, Wacholder S, Alfaro M, Morales J, Guillen D, Sherman ME, Solomon D, Schiffman M: Proyecto Epidemiológico Guanacaste (PEG) Group: Short term persistence of human papillomavirus and risk of cervical precancer and cancer: population based cohort study. BMJ 2009, 339:b2569.
• [12]Molano M, Van den Brule A, Plummer M, Weiderpass E, Posso H, Arslan A, Meijer CJ, Muñoz N, Franceschi S: HPV Study Group: Determinants of clearance of human papillomavirus infections in Colombian women with normal cytology: a population-based, 5-year follow-up study. Am J Epidemiol 2003, 158:486-494.
• [13]Oh JK, Ju YH, Franceschi S, Quint W, Shin HR: Acquisition of new infection and clearance of type-specific human papillomavirus infections in female students in Busan, South Korea: a follow-up study. BMC Infect Dis 2008, 8:13-18. BioMed Central Full Text
• [14]Kadish AS, Ho GY, Burk RD, Wang Y, Romney SL, Ledwidge R, Angeletti RH: Lymphoproliferative responses to human papillomavirus (HPV) type 16 proteins E6 and E7: outcome of HPV infection and associated neoplasia. J Natl Cancer Inst 1997, 89:1285-1293.
• [15]Song SH, Lee JK, Lee NW, Saw HS, Kang JS, Lee KW: Interferon-γ (IFN-γ): a possible prognostic marker for clearance of high-risk human papillomavirus (HPV). Gynecol Oncol 2008, 108:543-548.
• [16]Einstein KH, Schiller JT, Viscidi RP, Strickler HD, Coursaget P, Tan T, Halsey N, Jenkins D: Clinician’s guide to human papillomavirus immunology: knowns and unknowns. Lancet Infect Dis 2009, 9:347-356.
• [17]Sun XW, Kuhn L, Ellerbrock TV, Chiasson MA, Bush TJ, Wright TC Jr: Human papillomavirus infection in women infected with the human immunodeficiency virus. N Engl J Med 1997, 337:1343-1349.
• [18]Ahdieh L, Klein RS, Burk R, Cu-Uvin S, Schuman P, Duerr A, Safaeian M, Astemborski J, Daniel R, Shah K: Prevalence, incidence and type-specific persistence of human papillomavirus in human immunodeficiency virus (HIV)-positive and HIV-negative women. J Infect Dis 2001, 184:682-690.
• [19]Branca M, Garbuglia AR, Benedetto A, Cappiello T, Leoncini L, Migliore G, Agarossi A, Syrjänen K: DIANAIDS Collaborative Study Group: Factors predicting the persistence of genital human papillomavirus infections and PAP smear abnormality in HIV-positive and HIV-negative women during prospective follow-up. Int J STD Aids 2003, 14:417-425.
• [20]Strickler HD, Burk RD, Fazzari M, Anastos K, Minkoff H, Massad LS, Hall C, Bacon M, Levine AM, Watts DH, Silverberg MJ, Xue X, Schlecht NF, Melnick S, Palefsky JM: Natural history and possible reactivation of human papillomavirus in human immunodeficiency virus-positive women. J Natl Cancer Inst 2005, 97:577-586.
• [21]Rowhani-Rahbar A, Hawes SE, Sow PS, Toure P, Feng Q, Dem A, Dembele B, Critchlow CW, N’Doye I, Kiviat NB: The impact of HIV status and type on the clearance of human papillomavirus infection among Senegalese women. J Infect Dis 2007, 196:887-894.
• [22]Paramsothy P, Jamieson DJ, Heilig CM, Schuman PC, Klein RS, Shah KV, Rompalo AM, Cu-Uvin S, Duerr A: The effect of highly active antiretroviral therapy on human papillomavirus clearance and cervical cytology. Obstet Gynecol 2009, 113:26-31.
• [23]Takakuwa K, Mitsui T, Iwashita M, Kobayashi I, Suzuki A, Oda T, Torii Y, Matsumoto M, Yahata G, Tanaka K: Studies on the prevalence of human papillomavirus in pregnant women in Japan. J Perinat Med 2006, 34:77-79.
• [24]Banura C, Franceschi S, van Doorn LJ, Arslan A, Kleter B, Wabwire-Mangen F, Mbidde EK, Quint W, Weiderpass E: Prevalence, incidence and clearance of human papillomavirus infection among young primiparous pregnant women in Kampala, Uganda. Int J Cancer 2008, 123:2180-2187.
• [25]Domza G, Gudleviciene Z, Didziapetriene J, Valuckas KP, Kazbariene B, Drasutiene G: Human papillomavirus infection in pregnant women. Arch Gynecol Obstet 2010, 20:1405-1410.
• [26]Fife KH, Katz BP, Brizendine EJ, Brown DR: Cervical human papillomavirus deoxyribonucleic acid persists throughout pregnancy and decreases in the postpartum period. Am J Obstet Gynecol 1999, 180:1110-1114.
• [27]Nobbenhuis MAE, Helmerhorst TJM, van den Brule AJC, Rozendaal L, Bezemer PD, Voorhorst FJ, Meijer CJ: High-risk human papillomavirus clearance in pregnant women: trends for lower clearance during pregnancy with a catch-up postpartum. Br J Cancer 2002, 87:75-80.
• [28]Ziegler A, Kastner C, Chang-Claude J: Analysis of pregnancy and other factors on detection of human papillomavirus (HPV) infection using weighted estimating equations for follow-up data. Statist Med 2003, 22:2217-2233.
• [29]Sarkola ME, Grénman SE, Rintala MA, Syrjanen KJ, Syrjanen SM: Effect of second pregnancy on maternal carriage and outcome of high-risk human papillomavirus (HPV). Experience from the prospective finnish family HPV study. Gynecol Obstet Invest 2009, 67:208-216.
• [30]Minkoff H, Shen X, Watts DH, Leighty R, Hershow R, Palefsky J, Tuomala R, Neu N, Zorrilla CD, Paul M, Strickler H: Relationship of pregnancy to human papillomavirus among human immunodeficiency virus-infected women. Obstet Gynecol 2006, 108:953-960.
• [31]de Roda-Husman AM, Walboomers JMM, van den Brule AJC, Meijer CJLM, Snijders PJF: The use of general primers GP5 and GP6 elongated at their 3′ ends with adjacent highly conserved sequences improves human papillomavirus detection by PCR. J Gen Virology 1995, 76:1057-1062.
• [32]Mant C, Kell B, Best JM, Cason J: Polymerase chain reaction protocols for the detection of DNA from mucosal human papillomavirus types -6, -11, -16, -18, -31 and -33. J Virol Methods 1997, 66:169-178.
• [33]Bernard HU, Chan SY, Manos MM, Ong CK, Villa LL, Delius H, Peyton CL, Bauer HM, Wheeler CM: Identification and assessment of known and novel human papillomaviruses by polymerase chain reaction amplification, restriction fragment length polymorphisms, nucleotide sequence and phylogenetic algorithms. J Infect Dis 1994, 170:1077-1085.
• [34]Winer RL, Hughes JP, Feng Q, O’Reilly S, Kiviat NB, Holmes KK, Koutsky LA: Condom use and the risk of genital human papillomavirus infection in young women. N Engl J Med 2006, 354:2654-54.
• [35]Goodman MT, Shvetsov YB, McDuffie K, Wilkens LR, Zhu X, Thompson PJ, Ning L, Killeen J, Kamemoto L, Hernandez BY: Prevalence, acquisition, and clearance of cervical human papillomavirus infection among women with normal cytology: Hawaii Human Papillomavirus Cohort Study. Cancer Res 2008, 68:8813-8824.
• [36]Castellsagué X, Drudis T, Cañadas MP, Goncé A, Ros R, Pérez JM, Quintana MJ, Muñoz J, Albero G, de Sanjosé S, Bosch FX: Human papillomavirus (HPV) infection in pregnant women and mother-to-child transmission of genital HPV genotypes: a prospective study in Spain. BCM Infect Dis 2009, 9:74-84.
• [37]Sellors JW, Karwalajtys TL, Kaczorowski J, Mahony JB, Lytwyn A, Chong S, Sparrow J, Lorincz A: Survey of HPV in Ontario Women Group: Incidence, clearance and predictors of human papillomavirus infection in women. CMAJ 2003, 168:421-425.
• [38]Richardson H, Abrahamowicz M, Tellier PP, Kelsall G, du Berger R, Ferenczy A, Coutlée F, Franco EL: Modifiable risk factors associated with clearance of type-specific cervical human papillomavirus infections in a cohort of university students. Cancer Epidemiol Biomarkers Prev 2005, 14:1149-1156.
• [39]Lai CH, Chao A, Chang CJ, Chao FY, Huang HJ, Hsueh S, Lin CT, Cheng HH, Huang CC, Yang JE, Wu TI, Chou HH, Chang TC: Host and viral factors in relation to clearance of human papillomavirus infection: a cohort study in Taiwan. Int J Cancer 2008, 123:1685-1692.
• [40]Rosa MI, Fachel JMG, Rosa DD, Medeiros LR, Igansi CR, Bozzetti MC: Persistence and clearance of human papillomavirus infection: a prospective cohort study. Am J Obstet Gynecol 2008., 199617.e1–617.e7
• [41]Bae J, Seo S-S, Park Y-S, Dong SM, Kang S, Myung SK, Park SY: Natural history of persistent high-risk human papillomavirus infections in Korean women. Gynecol Oncol 2009, 115:75-80.
• [42]Banura C, Sandin S, van Doorn LJ, Quint W, Kleter B, Wabwire-Mangen F, Mbidde EK, Weiderpass E: Type-specific incidence, clearance and predictors of cervical human papillomavirus infections (HPV) among young women: a prospective study in Uganda. Infect Agent Cancer 2010, 5:7. BioMed Central Full Text
• [43]Ahdoot D, van Nostrand KM, Nguyen NJ, Tewari DS, Kurasaki T, DiSaia PJ, Rose GS: The effect of route of delivery on regression of abnormal cervical cytologic findings in the postpartum period. Am J Obstet Gynecol 1998, 178:1116-20.
• [44]Ueda Y, Enomoto T, Miyatake T, Yoshino K, Fujita M, Miyake T, Fujiwara K, Muraji M, Kanagawa T, Kimura T: Postpartum outcome of cervical intraepithelial neoplasia in pregnant women determined by route of delivery. Reprod Sci 2009, 16:1034-9.
• [45]Yost NP, Santoso JT, McIntire DD, Iliya FA: Postpartum regression rates of antepartum cervical intraepithelial neoplasia II and III lesions. Obstet Gynecol 1999, 93:359-62.
• [46]Kaneshiro BE, Acoba JD, Holzman J, Wachi K, Carney ME: Effect of delivery route on natural history of cervical dysplasia. Am J Obstet Gynecol 2005, 192:1452-1454.
• [47]Denny L, Boa R, Williamson AL, Allan B, Hardie D, Stan R, Myer L: Human papillomavirus infection and cervical disease in human immunodeficiency virus-1-infected women. Obstet Gynecol 2008, 111:1380-7.
• [48]Blitz S, Baxter J, Raboud J, Walmsley S, Rachlis A, Smaill F, Ferenczy A, Coutlée F, Hankins C, Money D: Canadian Women’s HIV Study Group: Evaluation of HIV and highly active antiretroviral therapy on the natural history of human papillomavirus infection and cervical cytopathologic findings in HIV-positive and high-risk HIV-negative women. J Infect Dis 2013, 208(3):454-62.
• [49]Schiffman M, Wentzensen N, Wacholder S, Kinney W, Gage JC, Castle PE: Human papillomavirus testing in the prevention of cervical cancer. J Natl Cancer Inst 2011, 103:368-83.